ArticleVeterinary sciences2026
Antiviral Activity of Baicalin Against PRRSV In Vitro and in Infected Piglets.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) causes substantial losses to the swine industry, creating a need for complementary antiviral interventions. This study evaluated the antiviral and protective effects of baicalin against PRRSV in vitro and in vivo. Cytotoxicity and antiviral activity were assessed in porcine alveolar macrophages (PAMs), and stage-specific assays were used to identify the affected phase of infection. Twenty piglets were assigned to Mock, baicalin, PRRSV, and PRRSV plus baicalin groups to evaluate clinical outcomes, viremia, respiratory shedding, tissue lesions, and inflammatory responses. Baicalin did not markedly affect PAM viability at concentrations up to 80 μg/mL. Within the tested non-cytotoxic concentration range, baicalin was associated with concentration-dependent reductions in infectious virus titers and PRRSV nsp9 mRNA levels. Among the stage-specific conditions examined, the greatest reduction in progeny virus production was observed when baicalin was present during the viral attachment phase, whereas no significant effects were detected in the direct virucidal, entry, intracellular replication, or progeny-release assays under the tested conditions. Compared with the PRRSV group, the PRRSV plus baicalin group showed lower viral loads in serum, oropharyngeal swabs, and nasal swabs at multiple sampling time points, together with less pronounced fever and clinical signs and partial preservation of body-weight gain. By the end of the experiment, four of five piglets survived in the PRRSV plus baicalin group, compared with one of five piglets in the PRRSV group. Serum IL-1β, IL-6, IL-8, and TNF-α concentrations were also lower in the PRRSV plus baicalin group at several sampling time points. Collectively, baicalin showed antiviral activity against PRRSV in PAMs, with the greatest activity observed when it was present during the viral attachment phase. In piglets, prophylactic dietary baicalin supplementation was associated with lower viral burden and less severe clinical, inflammatory, and pathological changes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.